2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American …

…, M Fischbach, M Frosch, R Gallizzi… - Arthritis & …, 2016 - Wiley Online Library
Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

…, D Rigante, S Al-Mayouf, I Touitou, R Gallizzi… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the response to treatment of autoinflammatory diseases from an
international registry and an up-to-date literature review. Methods The response to treatment was …

Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

…, AE Christensen, I Foeldvari, R Gallizzi… - The Lancet Child & …, 2019 - thelancet.com
Background To our knowledge, the characteristics and burden of childhood arthritis have
never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study…

Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children

…, SM Al-Mayouf, G Fabio, R Gallizzi… - Annals of the …, 2014 - ard.bmj.com
Background and aim Familial Mediterranean fever (FMF) is an autoinflammatory disease
caused by mutations of the MEFV gene. We analyse the impact of ethnic, environmental and …

MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement

…, S D'Arrigo, F Emma, E Fazzi, R Gallizzi… - Human …, 2009 - Wiley Online Library
The acronym COACH defines an autosomal recessive condition of Cerebellar vermis hypo/aplasia,
Oligophrenia, congenital Ataxia, Coloboma and Hepatic fibrosis. Patients present the …

[HTML][HTML] Intestinal Behçet and Crohn's disease: two sides of the same coin

S Valenti, R Gallizzi, D De Vivo, C Romano - Pediatric Rheumatology, 2017 - Springer
Behçet’s disease (BD) and Crohn’s disease (CD) are chronic immune-mediated, inflammatory
disorders affecting many different systems (joints, skin, eyes, gastrointestinal and biliary …

[HTML][HTML] A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi …

…, G De Marchi, M Frassi, R Gallizzi… - Frontiers in …, 2016 - frontiersin.org
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic
options in a large number of old and new clinical entities characterized by an IL-1 driven …

[HTML][HTML] A national cohort study on pediatric Behçet's disease: cross-sectional data from an Italian registry

R Gallizzi, C Pidone, L Cantarini, M Finetti… - Pediatric …, 2017 - Springer
Background Behçet’s disease is a rare multi-systemic inflammatory disease with unknown
etiology which involves principally oral and genital mucosa, skin and eyes. Average age at …

Development of the autoinflammatory disease damage index (ADDI)

…, KL Durrant, G Fabio, R Gallizzi… - Annals of the …, 2017 - ard.bmj.com
Objectives Autoinflammatory diseases cause systemic inflammation that can result in damage
to multiple organs. A validated instrument is essential to quantify damage in individual …

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

…, R Talarico, G de Marchi, M Frassi, R Gallizzi… - Clinical …, 2018 - Springer
A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The
aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in …